

| Package | Price per Dose | Price | |
|---|---|---|---|
| 180 pills | C$11.86 | C$2,845.21 C$2,133.91 Free shipping | |
| 120 pills | C$12.06 | C$1,928.95 C$1,446.71 Free shipping | |
| 90 pills | C$12.26 | C$1,470.82 C$1,103.11 Free shipping | |
| 60 pills | C$12.46 | C$996.61 C$747.46 Free shipping | |
| 30 pills | C$12.66 | C$506.33 C$379.75 Free shipping | |
| 20 pills | C$12.86 | C$342.90 C$257.18 | |
| 10 pills | C$13.06 | C$174.12 C$130.59 | |
| 120 pills | C$15.71 | C$2,513.00 C$1,884.75 Free shipping | |
| 90 pills | C$15.99 | C$1,918.23 C$1,438.67 Free shipping | |
| 60 pills | C$16.28 | C$1,302.03 C$976.52 Free shipping | |
| 30 pills | C$16.42 | C$656.36 C$492.27 Free shipping | |
| 20 pills | C$16.58 | C$442.03 C$331.52 Free shipping | |
| 10 pills | C$16.68 | C$222.34 C$166.76 |
Hyponatremia—low blood sodium—can trigger confusion, fatigue, nausea and headaches, and in severe cases seizures. Fluid overload from SIADH or advanced heart failure can worsen symptoms. Tolvaptan tackles these problems by blocking vasopressin V2 receptors in the kidney. The result is free-water loss (aquaresis) with a gradual rise in serum sodium. Tolvaptan is used as an oral medication for hyponatremia and, in adults with autosomal dominant polycystic kidney disease (ADPKD), to slow cyst growth.
Tolvaptan belongs to the vasopressin receptor antagonists. It blocks V2 receptors in the collecting ducts, promoting aquaresis and gradually correcting sodium levels. In ADPKD, tolvaptan may slow cyst growth and preserve kidney function in carefully selected adults. The medicine is taken orally, typically once daily, under medical supervision.
Within this class, tolvaptan is oral and V2-selective. Conivaptan is intravenous and blocks both V1A and V2 receptors. Both aim to correct hyponatremia, but they differ in administration, selectivity and monitoring needs. Hepatic safety signals exist for both, and rapid sodium correction is a risk with either. Tolvaptan’s use in ADPKD also distinguishes it from purely hyponatremia-focused alternatives.
Hyponatremia due to SIADH, and hyponatremia associated with heart failure or other causes where careful water balance is needed. In adults with ADPKD, tolvaptan is indicated to slow cyst progression and preserve kidney function.
Comparing a few alternatives clarifies use and safety.
| Drug | Mechanism | Route | Indications |
|---|---|---|---|
| Tolvaptan | V2-selective vasopressin receptor antagonist | Oral | Hyponatremia; ADPKD (adults) |
| Conivaptan | V1A and V2 antagonist | Intravenous | Hyponatremia in hospitalized patients |
| Demeclocycline | Renal resistance to vasopressin (not a receptor antagonist) | Oral | Historical/rare hyponatremia management |
Common side effects include thirst, dry mouth, increased urination and headache. Monitor sodium to avoid overly rapid correction, which can cause neurologic injury. Tolvaptan carries a risk of liver injury with long-term use, so baseline and periodic liver-function tests are advised. It is generally avoided in pregnancy and in significant liver impairment. Use caution with strong CYP3A4 inhibitors or dehydration-prone conditions.
14–21 days. Free from C$287.05 .
5–9 days. C$43.06
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
